Skip to main content
SpringerLink
Log in

Overview and Initial Management of Cushing Syndrome

  • Chapter
  • First Online:
Endocrine Conditions in Pediatrics

  • 1179 Accesses

Abstract

Cushing syndrome is characterized by chronic exposure to supra-physiologic glucocorticoid levels, which may be exogenous or endogenous, manifesting as a constellation of clinical symptoms and signs that vary with the severity and duration of glucocorticoid excess. When hypercortisolism is severe, it reveals itself quite distinctively. However, the pathognomonic signs and symptoms of Cushing syndrome are not always present in every individual. The clinical phenotype ranges from changes in body habitus, moon facies, central obesity, a dorsocervical fat pad, proximal muscle weakness, and easy bruising, to frank diabetes, hypertension, and dyslipidemia. Cushing syndrome may additionally disturb the reproductive system (causing amenorrhea, hypogonadism, and erectile dysfunction) and may be associated with mood lability, anxiety, depression, and cognitive decline. In children, glucocorticoid excess may result in statural growth failure in the setting of weight gain. The wide spectrum of manifestations can make the diagnosis particularly challenging. Available screening tests also have their caveats, which makes it fundamental to individualize diagnostic testing, depending upon each patient’s situation, including their lifestyle. It is crucial to clearly demonstrate cortisol excess before pursuing evaluation of the etiology of Cushing syndrome. Prompt diagnosis enables clinicians to tailor the management plan to the individual and to optimize therapy while preventing comorbidities that significantly impair quality of life and increase mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. 2013;24:714–20.

    Article  CAS  PubMed  Google Scholar 

  2. Stratakis CA. Cushing syndrome in pediatrics. Endocrinol Metab Clin N Am. 2012;41:793–803.

    Article  Google Scholar 

  3. Stratakis CA. An update on Cushing syndrome in pediatrics. Ann Endocrinol (Paris). 2018;79:125–31.

    Article  Google Scholar 

  4. Ambrogio AG, De Martin M, Ascoli P, et al. Gender-dependent changes in haematological parameters in patients with Cushing's disease before and after remission. Eur J Endocrinol. 2014;170:393–400.

    Article  CAS  PubMed  Google Scholar 

  5. Chrousos GP, Kino T, Charmandari E. Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence. Neuroimmunomodulation. 2009;16:272–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1526–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Karageorgiadis AS, Papadakis GZ, Biro J, et al. Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing Cushing syndrome: a diagnostic dilemma and how to solve it. J Clin Endocrinol Metab. 2015;100:141–8.

    Article  CAS  PubMed  Google Scholar 

  8. More J, Young J, Reznik Y, et al. Ectopic ACTH syndrome in children and adolescents. J Clin Endocrinol Metab. 2011;96:1213–22.

    Article  CAS  PubMed  Google Scholar 

  9. Morin E, Mete O, Wasserman JD, et al. Carney complex with adrenal cortical carcinoma. J Clin Endocrinol Metab. 2012;97:E202–6.

    Article  CAS  PubMed  Google Scholar 

  10. Savage MO, Storr HL, Chan LF, Grossman AB. Diagnosis and treatment of pediatric Cushing's disease. Pituitary. 2007;10:365–71.

    Article  PubMed  Google Scholar 

  11. Lindholm J. Cushing's disease, pseudo-Cushing states and the dexamethasone test: a historical and critical review. Pituitary. 2014;17:374–80.

    Article  CAS  PubMed  Google Scholar 

  12. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet. 2015;386:913–27.

    Article  CAS  Google Scholar 

  13. Bonnet-Serrano F, Bertherat J. Genetics of tumors of the adrenal cortex. Endocr Relat Cancer. 2018;25:R131–52.

    Article  CAS  PubMed  Google Scholar 

  14. Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015;173:M33–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Suarez MG, Stack M, Hinojosa-Amaya JM, et al. Hypercoagulability in Cushing syndrome, prevalence of thrombotic events: a large, single-center, retrospective study. J Endocrinol Soc. 2020;4:bvz033.

    Article  Google Scholar 

  16. Andela CD, van Haalen FM, Ragnarsson O, et al. Mechanisms in endocrinology: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol. 2015;173:R1–14.

    Article  CAS  PubMed  Google Scholar 

  17. Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;7:281–93.

    PubMed  PubMed Central  Google Scholar 

  18. Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol. 2007;157:725–31.

    Article  CAS  PubMed  Google Scholar 

  19. Putignano P, Toja P, Dubini A, et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab. 2003;88:4153–7.

    Article  CAS  PubMed  Google Scholar 

  20. Burgess JR, Shepherd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab. 1996;81:2642–6.

    CAS  PubMed  Google Scholar 

  21. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93:1553–62.

    Article  CAS  PubMed  Google Scholar 

  22. Arendt J. Shift work: coping with the biological clock. Occup Med (Lond). 2010;60:10–20.

    Article  Google Scholar 

  23. Bansal V, El Asmar N, Selman WR, Arafah BM. Pitfalls in the diagnosis and management of Cushing's syndrome. Neurosurg Focus. 2015;38:E4.

    Article  PubMed  Google Scholar 

  24. Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab. 2006;91:3725–45.

    Article  CAS  PubMed  Google Scholar 

  25. Coe CL, Murai JT, Wiener SG, et al. Rapid cortisol and corticosteroid-binding globulin responses during pregnancy and after estrogen administration in the squirrel monkey. Endocrinology. 1986;118:435–40.

    Article  CAS  PubMed  Google Scholar 

  26. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257–66.

    Article  CAS  PubMed  Google Scholar 

  27. Chan KC, Lit LC, Law EL, et al. Diminished urinary free cortisol excretion in patients with moderate and severe renal impairment. Clin Chem. 2004;50:757–9.

    Article  CAS  PubMed  Google Scholar 

  28. Mericq MV, Cutler GB Jr. High fluid intake increases urine free cortisol excretion in normal subjects. J Clin Endocrinol Metab. 1998;83:682–4.

    Article  CAS  PubMed  Google Scholar 

  29. Yilmaz N, Tazegul G, Bozoglan H, et al. Diagnostic value of the late-night salivary cortisol in the diagnosis of clinical and subclinical Cushing's syndrome: results of a single-center 7-year experience. J Investig Med. 2019;67:28–33.

    Article  PubMed  Google Scholar 

  30. Krieger DT, Allen W, Rizzo F, Krieger HP. Characterization of the normal temporal pattern of plasma corticosteroid levels. J Clin Endocrinol Metab. 1971;32:266–84.

    Article  CAS  PubMed  Google Scholar 

  31. Ploeger B, Mensinga T, Sips A, et al. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev. 2001;33:125–47.

    Article  CAS  PubMed  Google Scholar 

  32. Yaneva M, Mosnier-Pudar H, Dugue MA, et al. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab. 2004;89:3345–51.

    Article  CAS  PubMed  Google Scholar 

  33. Chiodini I, Ramos-Rivera A, Marcus AO, Yau H. Adrenal hypercortisolism: a closer look at screening, diagnosis, and important considerations of different testing modalities. J Endocrinol Soc. 2019;3:1097–109.

    Article  CAS  Google Scholar 

  34. Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999;130:821–4.

    Article  CAS  PubMed  Google Scholar 

  35. Ludecke D, Kautzky R, Saeger W, Schrader D. Selective removal of hypersecreting pituitary adenomas? An analysis of endocrine function, operative and microscopical findings in 101 cases. Acta Neurochir. 1976;35:27–42.

    Article  CAS  PubMed  Google Scholar 

  36. Carmalt MH, Dalton GA, Fletcher RF, Smith WT. The treatment of Cushing's disease by trans-sphenoidal hypophysectomy. Q J Med. 1977;46:119–34.

    CAS  PubMed  Google Scholar 

  37. Salassa RM, Laws ER Jr, Carpenter PC, Northcutt RC. Transsphenoidal removal of pituitary microadenoma in Cushing's disease. Mayo Clin Proc. 1978;53:24–8.

    CAS  PubMed  Google Scholar 

  38. Tyrrell JB, Brooks RM, Fitzgerald PA, et al. Cushing's disease. Selective trans-sphenoidal resection of pituitary microadenomas. N Engl J Med. 1978;298:753–8.

    Article  CAS  PubMed  Google Scholar 

  39. Wajchenberg BL, Silveira AA, Goldman J, et al. Evaluation of resection of pituitary microadenoma for the treatment of Cushing's disease in patients with radiologically normal sella turcica. Clin Endocrinol. 1979;11:323–31.

    Article  CAS  Google Scholar 

  40. Guthrie FW Jr, Ciric I, Hayashida S, et al. Pituitary Cushing's syndrome and Nelson's syndrome: diagnostic criteria, surgical therapy, and results. Surg Neurol. 1981;16:316–23.

    Article  PubMed  Google Scholar 

  41. Boggan JE, Tyrrell JB, Wilson CB. Transsphenoidal microsurgical management of Cushing's disease. Report of 100 cases. J Neurosurg. 1983;59:195–200.

    Article  CAS  PubMed  Google Scholar 

  42. Burch WM. Cushing's disease. A review. Arch Intern Med. 1985;145:1106–11.

    Article  CAS  PubMed  Google Scholar 

  43. Brand IR, Dalton GA, Fletcher RF. Long-term follow up of trans-sphenoidal hypophysectomy for Cushing's disease. J R Soc Med. 1985;78:291–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Nakane T, Kuwayama A, Watanabe M, et al. Long term results of transsphenoidal adenomectomy in patients with Cushing's disease. Neurosurgery. 1987;21:218–22.

    Article  CAS  PubMed  Google Scholar 

  45. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med. 1988;109:487–93.

    Article  CAS  PubMed  Google Scholar 

  46. Pieters GF, Hermus AR, Meijer E, et al. Predictive factors for initial cure and relapse rate after pituitary surgery for Cushing's disease. J Clin Endocrinol Metab. 1989;69:1122–6.

    Article  CAS  PubMed  Google Scholar 

  47. McCance DR, Gordon DS, Fannin TF, et al. Assessment of endocrine function after transsphenoidal surgery for Cushing's disease. Clin Endocrinol. 1993;38:79–86.

    Article  CAS  Google Scholar 

  48. Blevins LS Jr, Christy JH, Khajavi M, Tindall GT. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab. 1998;83:63–7.

    CAS  PubMed  Google Scholar 

  49. Semple PL, Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. J Neurosurg. 1999;91:175–9.

    Article  CAS  PubMed  Google Scholar 

  50. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Simeoli C, Ferrigno R, De Martino MC, et al. The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. J Endocrinol Investig. 2020;43:57–73.

    Article  CAS  Google Scholar 

  52. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev. 1993;14:443–58.

    Article  CAS  PubMed  Google Scholar 

  53. Findling JW, Raff H. Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91:3746–53.

    Article  CAS  PubMed  Google Scholar 

  54. Tritos NA, Biller BMK. Medical management of Cushing disease. Neurosurg Clin N Am. 2019;30:499–508.

    Article  PubMed  Google Scholar 

  55. Schteingart DE. Drugs in the medical treatment of Cushing's syndrome–an update on mifepristone and pasireotide. Expert Opin Emerg Drugs. 2012;17:279–83.

    Article  CAS  PubMed  Google Scholar 

  56. Alexandraki KI, Grossman AB. Medical therapy of Cushing's disease: where are we now? Front Horm Res. 2010;38:165–73.

    Article  PubMed  Google Scholar 

  57. Fleseriu M. Medical management of persistent and recurrent Cushing disease. Neurosurg Clin N Am. 2012;23:653–68.

    Article  PubMed  Google Scholar 

  58. Fleseriu M, Petersenn S. Medical management of Cushing's disease: what is the future? Pituitary. 2012;15:330–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. van der Pas R, de Herder WW, Hofland LJ, Feelders RA. New developments in the medical treatment of Cushing's syndrome. Endocr Relat Cancer. 2012;19:R205–23.

    Article  PubMed  Google Scholar 

  60. Cuevas-Ramos D, Fleseriu M. Medical treatment of Cushing's disease. Minerva Endocrinol. 2016;41:324–40.

    PubMed  Google Scholar 

  61. Feelders RA, Hofland LJ. Medical treatment of Cushing's disease. J Clin Endocrinol Metab. 2013;98:425–38.

    Article  CAS  PubMed  Google Scholar 

  62. Nieman LK. Update in the medical therapy of Cushing's disease. Curr Opin Endocrinol Diabetes Obes. 2013;20:330–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Gadelha MR, Vieira Neto L. Efficacy of medical treatment in Cushing's disease: a systematic review. Clin Endocrinol. 2014;80:1–12.

    Article  CAS  Google Scholar 

  64. Tritos NA, Biller BM. Medical management of Cushing's disease. J Neuro-Oncol. 2014;117:407–14.

    Article  Google Scholar 

  65. Fleseriu M. Recent advances in the medical treatment of Cushing's disease. F1000Prime Rep. 2014;6:18.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Tritos NA, Biller BM. Update on radiation therapy in patients with Cushing's disease. Pituitary. 2015;18:263–8.

    Article  CAS  PubMed  Google Scholar 

  67. Broersen LHA, Andela CD, Dekkers OM, et al. Improvement but no normalization of quality of life and cognitive functioning after treatment of cushing syndrome. J Clin Endocrinol Metab. 2019;104:5325–37.

    PubMed  Google Scholar 

  68. Dekkers OM, Horvath-Puho E, Jorgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: a cohort study. J Clin Endocrinol Metab. 2013;98:2277–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA, USA

    Soundos Youssef & Vibha Singhal

  2. Division of Pediatric Endocrinology, Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Vibha Singhal

Authors
  1. Soundos Youssef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vibha Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Soundos Youssef .

Editor information

Editors and Affiliations

  1. Division of Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Takara Stanley

  2. Division of Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Madhusmita Misra

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Youssef, S., Singhal, V. (2021). Overview and Initial Management of Cushing Syndrome. In: Stanley, T., Misra, M. (eds) Endocrine Conditions in Pediatrics. Springer, Cham. https://doi.org/10.1007/978-3-030-52215-5_50

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52215-5_50

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52214-8

  • Online ISBN: 978-3-030-52215-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation